Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate the Safety, Efficacy, and Pharmacokinetics of BAY 73-4506 "Regorafenib", Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer

NCT01187615 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01187615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01187615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate the Safety, Efficacy, and Pharmacokinetics of BAY 73-4506 "Regorafenib", Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2010
Completion date
June 30, 2012
Enrollment
9 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma